NCT04566432Completed
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICIs) or Targeted Therapy
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 252 (actual)
- First submitted
- 23 Jul 2020
- Start date
- 1 Jul 2020
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Geneplus-Beijing Co. Ltd.
- Diseases
- Lung cancer
- NCT number
- NCT04566432
What you commit to
- Study type: Observational
- Participants enrolled: 252
- From 1 Jul 2020 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients have other primary cancers
- Patients have symptomatic brain metastasis, complications that are associated with brain metastasis or cognitive disorders
Other
- Patients failed in either plasma or tissue sample QC
Who the study is looking for
- Provision of informed consent
- Newly diagnosed and histological or cytological confirmed stage IIIB-IV lung adenocarcinoma or squamous cell carcinoma patients according to the AJCC staging system. The stage IV lung cancer and brain metastasis can be diagnosed by imaging and enhanced CT respectively
- No EGFR mutation in tissue and ctDNA
- Received immune checkpoint inhibitors as the first line therapy
- ECOG performance status 0-2 with expected more than 6 months of survival time
- Willingness to comply with required protocols and give permission to use the data for clinical research and products development
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.